Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

四川百利天恒药业近日发布2024年业绩预告，预计营收同比增长932.27%，扭亏为盈，主要因其于2024年内收到海外合作伙伴Bristol-Myers Squibb Company基于合作协议支付的8亿美元首付款。百利天恒的核心产品BL-B01D1是一种EGFR×HER3双特异性抗体ADC药物，虽然有望成为基石泛肿瘤疗法，但与同类药物比较后，其治疗相关不良事件发生率或更高。此外，其他药企的HER3 ...